Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate based on enhanced spike protein design
- Details
- Category: Pfizer

AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager
- Details
- Category: AstraZeneca

The acquisition of TNB-486 aims to accelerate the development of this potential new medicine for B-cell haematologic malignancies, including diffuse large B-cell lymphoma and follicular lymphoma.
Pfizer and BioNTech complete submission to European Medicines Agency for Omicron BA.1 adapted bivalent vaccine candidate
- Details
- Category: Pfizer

Bayer to sell men's health product Nebido™ to Grünenthal
- Details
- Category: Bayer

Nebido for the treatment of male hypogonadism (testosterone deficiency) is available in over 80 countries since 2004. In 2021, the product contributed sales of 117 million Euro to Bayer's overall sales of more than 44 billion Euro.
Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government
- Details
- Category: Eli Lilly and Company

Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries
- Details
- Category: Sanofi

The Impact® brand, which includes insulin, glibenclamide and oxaliplatin amonst others, will enable the secure distribution of 30 Sanofi medicines in 40 lower-income countries.
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
- Details
- Category: Boehringer Ingelheim

More Pharma News ...
- FDA grants Priority Review to Roche’s Lunsumio for people with relapsed or refractory follicular lymphoma
- GSK completes acquisition of Sierra Oncology
- Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
- Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
- New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
- Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron
- GSK announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countries